Which disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis is typically the least expensive?

Methotrexate is typically considered the least expensive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. This is attributed to its long-standing availability, widespread use, and the fact that it has been on the market for many years, leading to lower costs associated with manufacturing and purchasing. Methotrexate is often used as a first-line treatment for rheumatoid arthritis due to its efficacy in reducing inflammation and slowing disease progression, while also being budget-friendly for patients and the healthcare system.

In comparison, although hydroxychloroquine and sulfasalazine can also be relatively low in cost, they may not be as universally used or effective as methotrexate for the majority of patients with rheumatoid arthritis. Leflunomide tends to be more expensive due to its more recent introduction to the market and the cost of newer formulations. This perspective highlights Methotrexate's status as the most cost-effective option among these DMARDs.